CLOs on the Move

Diamedica

www.diamedica.com

 
DiaMedica Inc., a development stage biopharmaceutical company, is engaged in the discovery and development of drugs for the treatment of diabetes and related diseases. The company`s lead clinical stage compound is DM199, a recombinant human protein known as rhKLK1, which is under phase I/II clinical trials for the treatment of Type 1 and Type 2 diabetes and associated complications. It is also developing DM204, a monoclonal antibody that is in preclinical development for the treatment of Type 2 diabetes; and DMDx, a chronic kidney disease assay to detect levels of the tissue kallikrein-1 protein in urine and to predict the ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.diamedica.com
  • Two Carlson Parkway Suite 260
    Minneapolis, MN USA 55447
  • Phone: 763.496.5454

Executives

Name Title Contact Details

Similar Companies

Atlanta Oral & Facial Surgery

Atlanta Oral & Facial Surgery is a local, trusted dental practice offering expert dentistry in Atlanta, GA. Contact us and schedule your appointment today!

Girling Health Care

The Girling Difference Girling Health Care of NY is a leading provider of home health and home concierge care services. We provide personalized, professional care for patients in the comfort of their homes. Our services include home companions, skilled...

Family Guidance Centers

Since 1980, we have been offering our clients experienced and compassionate clinical care, which gives us the distinction of having served the people of Chesterfield longer than any other private mental health group practice in the county. Our staff of...

MassMEDIC

The Heart of Healthtech Beats Here. We proudly serve as the voice of the #healthtech industry in New England, representing companies changing the world.

Cognito Therapeutics

Cognito Therapeutics is a pioneer in non-invasive neuromodulation to treat neurodegenerative diseases and improve human cognitive performance. The company has completed multiple clinical studies demonstrating its investigational therapeutic has the potential to safely slow or stop cognitive decline and loss of brain volume in Alzheimer`s disease. Cognito has received FDA Breakthrough Device Designation for the treatment of Alzheimer`s disease and expects to start pivotal studies in 2022. The company`s technology was based on pioneering optogenetics research by scientific co-founders Professors Li-Huei Tsai and Ed Boyden at MIT.